{"id":"W4399564759","doi":"10.1136/bmjonc-2023-000181","title":"Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial","year":2024,"lang":"en","type":"article","venue":"BMJ Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"Genentech; Medac; Ipsen; National Institutes of Health; Shionogi; Ono Pharmaceutical; Astellas Pharma; Eisai; Chugai Pharmaceutical; Seagen; National Cancer Institute; Intuitive Surgical; Calithera Biosciences; Incyte; Pfizer; GlaxoSmithKline; Arrowhead Pharmaceuticals; PTC Therapeutics; Sanofi; Exelixis; Genomic Health; Les Laboratories Pierre Fabre; AstraZeneca; Bristol-Myers Squibb","keywords":"Avelumab; Medicine; Sunitinib; Renal cell carcinoma; Axitinib; Post-hoc analysis; Internal medicine; Eosinophil; Oncology; Nivolumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005135388,0.0007806702,0.002256417,0.0002160611,0.0001991174,0.0009771149,0.0005998767,0.0005312929,0.001836299],"category_scores_gemma":[0.002995066,0.0002493846,0.004549589,0.0002939594,0.0003172915,0.0006935145,0.0004394919,0.001524579,0.0001787182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000392317,"about_ca_system_score_gemma":0.0005583363,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005180145,"about_ca_topic_score_gemma":0.001144437,"domain_scores_codex":[0.9975576,0.001615603,0.0001483187,0.0003308149,0.0001672798,0.0001802726],"domain_scores_gemma":[0.9970325,0.001541777,0.0006586846,0.0003016433,0.0001435094,0.0003219491],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7736374,0.001390657,0.1446024,0.001089562,0.04463532,0.0001811368,0.0001101786,0.004055064,0.006147725,0.0001246006,0.002365952,0.02166],"study_design_scores_gemma":[0.1060766,0.09347104,0.7296857,0.0001162503,0.04746385,0.0005072108,0.0001790455,0.01134976,0.005690356,0.0006808838,0.004657876,0.000121526],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953569,0.002574205,0.0003492823,0.0001497263,0.00007113656,0.00009599256,0.0008857281,0.00002021472,0.0004968236],"genre_scores_gemma":[0.9979002,0.0002680557,0.0001975166,0.00009910204,0.00008042675,0.0001002646,0.0009554995,0.00001125212,0.0003875943],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005135388,"threshold_uncertainty_score":0.02715886,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04883230815604549,"score_gpt":0.3487168361763055,"score_spread":0.29988452802026,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}